Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.24 (1y: -31%)
Market Cap 74.22 M P/E(ttm)
Enterprise Value 67.26 M P/B 9.80
CVM- AMEX (USA)
CEL-SCI Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$0.24
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt No Debt
CVM's Cash to Debt is ranked higher than
81% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CVM: No Debt )
CVM' s 10-Year Cash to Debt Range
Min: 0.85   Max: No Debt
Current: No Debt
Equity to Asset 0.437
CVM's Equity to Asset is ranked higher than
64% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. CVM: 0.437 )
CVM' s 10-Year Equity to Asset Range
Min: -0.1   Max: 0.96
Current: 0.44
-0.1
0.96
F-Score: 1
Z-Score: -8.55
M-Score: -1.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) -6762.00
CVM's Operating margin (%) is ranked lower than
60% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CVM: -6762.00 )
CVM' s 10-Year Operating margin (%) Range
Min: -190240   Max: -1269.2
Current: -6762
-190240
-1269.2
Net-margin (%) -6069.4
CVM's Net-margin (%) is ranked lower than
60% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CVM: -6069.4 )
CVM' s 10-Year Net-margin (%) Range
Min: -154060   Max: 6851.6
Current: -6069.4
-154060
6851.6
ROE (%) -220.3
CVM's ROE (%) is ranked lower than
60% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CVM: -220.3 )
CVM' s 10-Year ROE (%) Range
Min: -785.5   Max: 37.6
Current: -220.3
-785.5
37.6
ROA (%) -96.3
CVM's ROA (%) is ranked lower than
58% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CVM: -96.3 )
CVM' s 10-Year ROA (%) Range
Min: -238.1   Max: 27.7
Current: -96.3
-238.1
27.7
ROC (Joel Greenblatt) (%) -777.10
CVM's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CVM: -777.10 )
CVM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2848.9   Max: -504.2
Current: -777.1
-2848.9
-504.2
EBITDA Growth (%) -6.1
CVM's EBITDA Growth (%) is ranked higher than
52% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CVM: -6.1 )
CVM' s 10-Year EBITDA Growth (%) Range
Min: -48.6   Max: 15.8
Current: -6.1
-48.6
15.8
EPS Growth (%) -31.1
CVM's EPS Growth (%) is ranked lower than
58% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CVM: -31.1 )
CVM' s 10-Year EPS Growth (%) Range
Min: -41.4   Max: 29.6
Current: -31.1
-41.4
29.6
» CVM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q4 2011

CVM Guru Trades in Q4 2011

Jim Simons 243,814 sh (New)
» More
Q1 2012

CVM Guru Trades in Q1 2012

Jim Simons 318,914 sh (+30.8%)
» More
Q2 2012

CVM Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q1 2013

CVM Guru Trades in Q1 2013

Jim Simons 158,117 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CVM



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 9.80
CVM's P/B is ranked higher than
51% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. CVM: 9.80 )
CVM' s 10-Year P/B Range
Min: 2.35   Max: 55.33
Current: 9.8
2.35
55.33
P/S 384.62
CVM's P/S is ranked lower than
61% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. CVM: 384.62 )
CVM' s 10-Year P/S Range
Min: 17   Max: 400
Current: 384.62
17
400
EV-to-EBIT 12.3
CVM's EV-to-EBIT is ranked higher than
51% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. CVM: 12.3 )
CVM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 12.3

Valuation & Return

vs
industry		 vs
history
Price/Tangible Book 12
CVM's Price/Tangible Book is ranked higher than
56% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. CVM: 12 )
CVM' s 10-Year Price/Tangible Book Range
Min: 3.5   Max: 46.5
Current: 12
3.5
46.5
Forward Rate of Return (Yacktman) -15.84
CVM's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CVM: -15.84 )
CVM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.4   Max: -15.8
Current: -15.84
-50.4
-15.8

Business Description

CEL-SCI Corporation was incorporated on March 22, 1983, in the state of Colorado. It is engaged in developing new immune system based treatments for cancer and infectious diseases. The Company's most advanced product, Multikine, is being developed for the treatment of cancer. Multikine are designed to target the tumor micro-metastises that are mostly responsible for treatment failure. The basic idea of Multikine is to make current cancer treatments more successful. The lead indication is advanced primary head & neck cancer. Since Multikine is not tumor specific, it might also be applicable in many other solid tumors. Multikine is the first immunotherapeutic agent being developed as a first-line treatment for cancer. The Company also owns a pre-clinical technology called L.E.A.P.S., Ligand Epitope Antigen Presentation System. LEAPS is designed to potentially stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own. It operates in a competitive environment. CEL-SCI currently has eight patents issued in the United States and twenty-nine patent applications pending in Europe, Japan, China, India, Hong Kong, Canada and the United States. The company is regulated by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of biological and other drug products and in ongoing research and product development activities.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:LSR.Germany
» More Articles for CVM

Headlines

Articles On GuruFocus.com
CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 
CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 
CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK